TSO3 IN LABEL REVIEW FOR ITS STERIZONE® STERILIZATION SYSTEM
Company to submit Final Labeling to US Regulatory Authorities for Sterilizer accessories
Québec City, October 22, 2014 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Corporation”) an innovator in sterilization technology for medical devices in healthcare settings, today announced that after a series of communications with US Regulatory Authorities, the Company has submitted revised labeling for the sterilizer, and is now finalizing labeling for accessory devices such as the Biological and Chemical Indicators used as part of the sterilization system. Such revisions are required so that all components of the entire system (sterilizer and accessories) can be in final review simultaneously.
“Over the past few weeks, our interactions with the regulators have focused on the labeling review of the STERIZONE® VP4 Sterilizer” stated R.M (Ric) Rumble, President and CEO. “With progress made in those discussions, it is now time to make revisions to the submissions previously made for the sterilizer accessories. These accessories include the Biological and Chemical Indicators used in our sterilizer”, continued Mr. Rumble.
“We have tangible evidence that progress is being made towards final clearance of the new system and the Company will update accordingly as new developments occur” concluded Mr. Rumble.
Founded in 1998, TSO3’s activities encompass research, development, commercialization and licensing of sterilization processes for heat-sensitive medical devices, related equipment, accessories and consumable supplies. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company’s Web site at www.tso3.com.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
-30-Back to Posts